FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DUYK GEOFFREY M 		2. Issuer Name and Ticker or Trading Symbol

AERIE PHARMACEUTICALS INC [ AERI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/14/2017
(Street)

FORT WORTH, TX 76102
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/14/2017     M    6667   A $19.50   10067   D    
Common Stock   2/14/2017     F    2770   D $46.95   7297   D    
Common Stock   2/14/2017     M    10000   A $32.30   17297   D    
Common Stock   2/14/2017     F    6880   D $46.95   10417   D    
Common Stock   2/14/2017     M    13500   A $17.55   23917   D    
Common Stock   2/14/2017     F    5047   D $46.95   18870   D    
Common Stock   2/14/2017     M    28000   A $3.15   46870   D    
Common Stock   2/14/2017     F    1879   D $46.95   44991   D    
Common Stock   2/14/2017     S    20795   D $46.4563   (1) 24196   D    
Common Stock   2/15/2017     S    20796   D $46.8089   (2) 3400   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $19.50   2/14/2017     M         6667      (3) 6/8/2026   Common Stock   6667   $0.00   3333   (3) D    
Stock Option (right to buy)   $32.30   2/14/2017     M         10000      (4) 4/10/2025   Common Stock   10000   $0.00   0   D    
Stock Option (right to buy)   $17.55   2/14/2017     M         13500      (5) 6/11/2024   Common Stock   13500   $0.00   0   D    
Stock Option (right to buy)   $3.15   2/14/2017     M         28000      (6) 9/12/2023   Common Stock   28000   $0.00   0   D    

Explanation of Responses:
( 1)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.20 to $47.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
( 2)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.20 to $47.45, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
( 3)  This option vested ratably on each of the first eight monthly anniversaries of June 8, 2016 and, subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, is scheduled to vest ratably on each of the following four monthly anniversaries of such date.
( 4)  This option vested ratably on each of the first 12 monthly anniversaries of April 10, 2015.
( 5)  This option vested fully on June 11, 2015.
( 6)  This option vested ratably on each of the first 36 monthly anniversaries of September 12, 2013.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DUYK GEOFFREY M
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300
FORT WORTH, TX 76102 		X



Signatures
/s/ Richard J. Rubino, Attorney-in-Fact for Geoffrey M. Duyk 2/16/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aerie Pharmaceuticals Charts.
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aerie Pharmaceuticals Charts.